Objective: To identify the impact of lamivudine on HBV e antigen (HBeAg) seroconversion and HBV DNA level, and the appearance of Tyr-Met-Asn-Asp (YMDD) resistants. Methods: Forty-seven hepatitis B patients were trea- ...Objective: To identify the impact of lamivudine on HBV e antigen (HBeAg) seroconversion and HBV DNA level, and the appearance of Tyr-Met-Asn-Asp (YMDD) resistants. Methods: Forty-seven hepatitis B patients were trea- ted with oral lamivudine. ALT level and HBeAg were detected in the treatment on the zero, 3rd, 6th and 9th month respectively. The levels of HBV DNA and YMDD resistants were analyzed with PCR mi- croplate hybridization-ELISA. Results: After 9 months of treatment, HBV DNA be- came negative and ALT level was normal in 74% pa- tients. Among these patients, 17% patients had HBeAg converted to negative and anti-HBe antibody positive, whereas another 15% patients showed HBeAg negative. YMDD resistants appeared in 19 % patients (9/47). One, three and five resistants were detected in the treatment on the 3rd, 6th and 9th month respectively. Conclusions: Most HBV DNA in serum became nega- tive after 9 months of treatment, and the rate of HBeAg seroconversion was 17% (HBV DNA level was lower than 100 pg/ml before treatment). YMDD resistants appeared in 19% patients.展开更多
To investigate the feasibility of using free fetal DNA from maternal plasma as the source of fetal material in non invasive prenatal diagnosis, SRY gene of free DNA in maternal blood of 65 samples were analyzed by us...To investigate the feasibility of using free fetal DNA from maternal plasma as the source of fetal material in non invasive prenatal diagnosis, SRY gene of free DNA in maternal blood of 65 samples were analyzed by using primer extension preamplication (PEP) and probe microplate hybridization techniques. The results showed that the detection rate of SRY gene in maternal blood from women carrying male fetuses detected by probe microplate hybridization alone and probe microplate hybridization with PEP were 76.09 % (35/46) and 95.65 % (44/46) respectively, and there was a significant difference between them. The non detection rate of SRY gene in blood samples from women carrying female fetus was 100 % (19/19). It is indicated that probe microplate hybridization was an effective method in detecting trace fetal DNA from maternal plasma and the sensitivity could be substantially improved by combined use of the two techniques. Analysis of fetal DNA in maternal plasma can serve as an alternative for non invasive prenatal diagnosis.展开更多
文摘Objective: To identify the impact of lamivudine on HBV e antigen (HBeAg) seroconversion and HBV DNA level, and the appearance of Tyr-Met-Asn-Asp (YMDD) resistants. Methods: Forty-seven hepatitis B patients were trea- ted with oral lamivudine. ALT level and HBeAg were detected in the treatment on the zero, 3rd, 6th and 9th month respectively. The levels of HBV DNA and YMDD resistants were analyzed with PCR mi- croplate hybridization-ELISA. Results: After 9 months of treatment, HBV DNA be- came negative and ALT level was normal in 74% pa- tients. Among these patients, 17% patients had HBeAg converted to negative and anti-HBe antibody positive, whereas another 15% patients showed HBeAg negative. YMDD resistants appeared in 19 % patients (9/47). One, three and five resistants were detected in the treatment on the 3rd, 6th and 9th month respectively. Conclusions: Most HBV DNA in serum became nega- tive after 9 months of treatment, and the rate of HBeAg seroconversion was 17% (HBV DNA level was lower than 100 pg/ml before treatment). YMDD resistants appeared in 19% patients.
基金This project was supported by a grant from ScienceFoundation of Health Ministry(No.96 .2 - 112 ) and HubeiProvincial Natural Science Foundation(No.96 J0 6 8)
文摘To investigate the feasibility of using free fetal DNA from maternal plasma as the source of fetal material in non invasive prenatal diagnosis, SRY gene of free DNA in maternal blood of 65 samples were analyzed by using primer extension preamplication (PEP) and probe microplate hybridization techniques. The results showed that the detection rate of SRY gene in maternal blood from women carrying male fetuses detected by probe microplate hybridization alone and probe microplate hybridization with PEP were 76.09 % (35/46) and 95.65 % (44/46) respectively, and there was a significant difference between them. The non detection rate of SRY gene in blood samples from women carrying female fetus was 100 % (19/19). It is indicated that probe microplate hybridization was an effective method in detecting trace fetal DNA from maternal plasma and the sensitivity could be substantially improved by combined use of the two techniques. Analysis of fetal DNA in maternal plasma can serve as an alternative for non invasive prenatal diagnosis.
